Drug‐resistant cytomegalovirus (CMV) should be considered when viral shedding persists
after several weeks of therapy. The problem is most likely to arise in the setting of a severely …

Infections due to resistant human cytomegalovirus (CMV) are an emerging problem,
particularly in immunocompromised hosts. When managing such patients, clinicians should …

Drug resistant strains of human cytomegalovirus (HCMV) in patients at risk may increasingly
develop into a problem in the clinical setting. Genotypic resistance testing is becoming the …

Resistance of cytomegalovirus (CMV) to antiviral agents is a well-recognized phenomenon
that has been observed in the laboratory and in the clinical setting. Infections caused by …

This article reviews the biology of cytomegalovirus (CMV), the approved antiviral therapies,
and mechanisms of resistance to these drugs. The rates of resistance development in …

The emergence of human cytomegalovirus (HCMV) drug resistant strains is a life-
threatening condition in immunocompromised individuals with active HCMV infection …

Background Cytomegalovirus (CMV) infections are a major cause of disease among
immunocompromised patients. Prolonged antiviral therapy is often necessary to prevent or …

An increasing volume of information correlating CMV genotypes and drug susceptibility
phenotypes is becoming available. This will improve the interpretation of sequence-based …

Antiviral agents are commonly used for cytomegalovirus (CMV) prophylaxis or therapy after
solid organ transplantation. Until recently, the detection of drug‐resistant CMV in this setting …

Cytomegalovirus resistance to antivirals is a major problem in transplant recipients. We
evaluated the impact of five mutations (A594V, L595F, and E655K in the UL97 gene and …